Metabolite Biomarkers Predictive Of Renal Disease In Diabetic Patients
AssigneeJoslin Diabetes Center, Inc.
InventorsMonika A. Niewczas, Andrzej S. Krolewski
Life of this patent
Estimating the term…
Abstract
The present invention relates to biomarkers that are predictive of renal disease in patients who have diabetes. The present invention also provides methods of using such biomarkers to predict the risk that a diabetic patient will develop renal disease, and/or to identify a patient who has diabetes as being in need of a therapy to prevent or delay the onset of a renal disease.
Claims19
A method of predicting risk of developing renal disease in a patient who has diabetes, comprising:
- a) determining the levels of at least three metabolites selected from the group consisting of pseudouridine, C-glycosyltryptophan, myoinositol, threitol, p-cresol sulfate, 2-hydroxyisovalerate, 2-hydroxyisocaproate, glutaryl carnitine, N2, N2-dimethylguanosine, phenylacetylglutamine, arabitol, gulono-1,4-lactone, erythritol, erythronate, N4-acetylcytidine, urate, 2-hydroxyisocaproate, 2-oxoisoleucine, and 2-oxoisocaproate in a plasma or serum sample taken from the patient;
- b) comparing the levels of the metabolites in the sample from the patient to control levels of the metabolites;
- and
- c) predicting that the patient is at risk for developing renal disease when the levels of the metabolites in the sample from the patient are significantly higher than the control levels of the metabolites.
A method of identifying a patient who has diabetes as being in need of a therapy to prevent or delay the onset of a renal disease, comprising:
- a) determining the levels of at least three metabolites selected from the group consisting of pseudouridine, C-glycosyltryptophan, myoinositol, threitol, p-cresol sulfate, 2-hydroxyisovalerate, 2-hydroxyisocaproate, glutaryl carnitine, N2, N2-dimethylguanosine, phenylacetylglutamine, arabitol, gulono-1,4-lactone, erythritol, erythronate, N4-acetylcytidine, urate, 2-hydroxyisocaproate, 2-oxoisoleucine, and 2-oxoisocaproate in a plasma or serum sample taken from the patient;
- b) comparing the levels of the metabolites in the sample from the patient to control levels of the metabolites;
- and
- c) implementing a therapy to prevent or delay the onset of a renal disease in the patient when the levels of the metabolites in the sample from the patient are significantly higher than the control levels of the metabolites.
Dependencies are inferred from the claim text.